Lidorestat
Names
Biological Activity
[Description]:
Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used to treat chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation[1][2][3].
[Related Catalog]:
[Target]
IC50: 5 nM (Rldose reductase)[1]
[In Vitro]
From in vitro experiments, Lidorestat has a reported IC50 against recombinant human aldose reductase (/h/-ALR2) of 5 μM. Against recombinant human aldehyde reductase (/h/-ALR1), Lidorestat has a reported IC50 of 27,000 μM, yielding a selectivity of /h/-ALR1//h/-ALR2 of 5400:1[1][2].
[In Vivo]
Lidorestat (25 mg/kg/day; oral administration; twice daily; for 6 weeks; diabetic mice) treatment decreases fructose and reduces mortality in diabetic hAR-expressing mice. And Lidorestat does not affect weight[1]. Animal Model: Diabetic low-density lipoprotein (LDL) receptor-deficient [Ldlr(-/-)] mice[1] Dosage: 25 mg/kg/day Administration: Oral administration; twice daily; for 6 weeks Result: Diabetic hAR-expressing mice had decreased fructose and reduced mortality.
[References]
Chemical & Physical Properties
[ Density]:
1.55g/cm3
[ Boiling Point ]:
591.4ºC at 760 mmHg
[ Melting Point ]:
177-178 °C
[ Molecular Formula ]:
C18H11F3N2O2S
[ Molecular Weight ]:
376.35200
[ Flash Point ]:
311.4ºC
[ Exact Mass ]:
376.04900
[ PSA ]:
83.36000
[ LogP ]:
4.34370
[ Vapour Pressure ]:
7.87E-15mmHg at 25°C
[ Index of Refraction ]:
1.681
[ Storage condition ]:
2-8°C